Ahmed Aman

Prof. Dr. Ahmed Aman

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
PSPatty Sachamitr
Patty Sachamitr
JHJolene C. Ho
Jolene C. Ho
FCFelipe E. Ciamponi
Felipe E. Ciamponi
WBWail Ba-Alawi
Wail Ba-Alawi
FCFiona J. Coutinho
Fiona J. Coutinho
PDPeter B. Dirks
Peter B. Dirks
Glioblastoma (GBM) is a deadly cancer in which cancer stem cells (CSCs) sustain tumor growth and contribute to therapeutic resistance. Protein arginine methyltransferase 5 (PRMT5) has recently emerged as a promising target in GBM. Using two orthogonal-acting inhibitors of PRMT5 (GSK591 or LLY-283), we show that pharmacological inhibition of PRMT5 suppresses the growth of a cohort of 46 patient-derived GBM stem cell cultures, with the proneural subtype showing greater sensitivity. We show that PRMT5 inhibition causes widespread disruption of splicing across the transcriptome, particularly affecting cell cycle gene products. We identify a GBM splicing signature that correlates with the degree of response to PRMT5 inhibition. Importantly, we demonstrate that LLY-283 is brain-penetrant and significantly prolongs the survival of mice with orthotopic patient-derived xenografts. Collectively, our findings provide a rationale for the clinical development of brain penetrant PRMT5 inhibitors as treatment for GBM.

10 August 2020 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
GPGanna Posternak
Ganna Posternak
XTXiaojing Tang
Xiaojing Tang
PMPierre Maisonneuve
Pierre Maisonneuve
TJTing Jin
Ting Jin
HLHugo Lavoie
Hugo Lavoie
FSFrank Sicheri
Frank Sicheri

23 November 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
MMMark F. Mabanglo
Mark F. Mabanglo
BWBrian Wilson
Brian Wilson
MNMahmoud Noureldin
Mahmoud Noureldin
SKSerah W. Kimani
Serah W. Kimani
AMAhmed Mamai
Ahmed Mamai
MVMasoud Vedadi
Masoud Vedadi
Proteolysis-targeting chimeras (PROTACs) have been explored for the degradation of drug targets for more than two decades. However, only a handful of E3 ligase substrate receptors have been efficiently used. Downregulation and mutation of these receptors would reduce the effectiveness of such PROTACs. We recently developed potent ligands for DCAF1, a substrate receptor of EDVP and CUL4 E3 ligases. Here, we focus on DCAF1 toward the development of PROTACs for WDR5, a drug target in various cancers. We report four DCAF1-based PROTACs with endogenous and exogenous WDR5 degradation effects and high-resolution crystal structures of the ternary complexes of DCAF1-PROTAC-WDR5. The structures reveal detailed insights into the interaction of DCAF1 with various WDR5-PROTACs, indicating a significant role of DCAF1 loops in providing needed surface plasticity, and reflecting the mechanism by which DCAF1 functions as a substrate receptor for E3 ligases with diverse sets of substrates.

8 March 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
SBSamir H. Barghout
Samir H. Barghout
AAAhmed Aman
Ahmed Aman
KNKazem Nouri
Kazem Nouri
ZBZachary Blatman
Zachary Blatman
KAKaren Arevalo
Karen Arevalo
ASAaron Schimmer
Aaron Schimmer
TAK-243 is a first-in-class inhibitor of ubiquitin-like modifier activating enzyme 1 that catalyzes ubiquitin activation, the first step in the ubiquitylation cascade. Based on its preclinical efficacy and tolerability, TAK-243 has been advanced to phase I clinical trials in advanced malignancies. Nonetheless, the determinants of TAK-243 sensitivity remain largely unknown. Here, we conducted a genome-wide CRISPR/Cas9 knockout screen in acute myeloid leukemia (AML) cells in the presence of TAK-243 to identify genes essential for TAK-243 action. We identified BEN domain-containing protein 3 ( BEND3 ), a transcriptional repressor and a regulator of chromatin organization, as the top gene whose knockout confers resistance to TAK-243 in vitro and in vivo. Knockout of BEND3 dampened TAK-243 effects on ubiquitylation, proteotoxic stress, and DNA damage response. BEND3 knockout upregulated the ATP-binding cassette efflux transporter breast cancer resistance protein (BCRP; ABCG2) and reduced the intracellular levelsof TAK-243. TAK-243 sensitivity correlated with BCRP expression in cancer cell lines of different origins. Moreover, chemical inhibition and genetic knockdown of BCRP sensitized intrinsically resistant high-BCRP cells to TAK-243. Thus, our data demonstrate that BEND3 regulates the expression of BCRP for which TAK-243 is a substrate. Moreover, BCRP expression could serve as a predictor of TAK-243 sensitivity.

14 October 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MMMandeep K. Mann
Mandeep K. Mann
CZCarlos A. Zepeda-Velázquez
Carlos A. Zepeda-Velázquez
HGHéctor González-Álvarez
Héctor González-Álvarez
ADAiping Dong
Aiping Dong
TKTaira Kiyota
Taira Kiyota
MSMatthieu Schapira
Matthieu Schapira

8 January 2024 in Analytical Chemistry
Verified
Journal Article
Open access
MWMichael Woolman
Michael Woolman
TKTaira Kiyota
Taira Kiyota
SBSiham A. Belgadi
Siham A. Belgadi
NFNaohide Fujita
Naohide Fujita
AFAlexa Fiorante
Alexa Fiorante
AZArash Zarrine-Afsar
Arash Zarrine-Afsar
Picosecond infrared laser mass spectrometry (PIRL-MS) is shown, through a retrospective patient tissue study, to differentiate medulloblastoma cancers from pilocytic astrocytoma and two molecular subtypes of ependymoma (PF-EPN-A, ST-EPN-RELA) using laser-extracted lipids profiled with PIRL-MS in 10 s of sampling and analysis time. The average sensitivity and specificity values for this classification, taking genomic profiling data as standard, were 96.41 and 99.54%, and this classification used many molecular features resolvable in 10 s PIRL-MS spectra. Data analysis and liquid chromatography coupled with tandem high-resolution mass spectrometry (LC-MS/MS) further allowed us to reduce the molecular feature list to only 18 metabolic lipid markers most strongly involved in this classification. The identified 'metabolite array' was comprised of a variety of phosphatidic and fatty acids, ceramides, and phosphatidylcholine/ethanolamine and could mediate the above-mentioned classification with average sensitivity and specificity values of 94.39 and 98.78%, respectively, at a 95% confidence in prediction probability threshold. Therefore, a rapid and accurate pathology classification of select pediatric brain cancer types from 10 s PIRL-MS analysis using known metabolic biomarkers can now be available to the neurosurgeon. Based on retrospective mining of 'survival' versus 'extent-of-resection' data, we further identified pediatric cancer types that may benefit from actionable 10 s PIRL-MS pathology feedback. In such cases, aggressiveness of the surgical resection can be optimized in a manner that is expected to benefit the patient's overall or progression-free survival. PIRL-MS is a promising tool to drive such personalized decision-making in the operating theater.